Patents by Inventor Chaofeng LONG

Chaofeng LONG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-INFLUENZA VIRUS PYRIMIDINE DERIVATIVES
    Publication number: 20230339943
    Abstract: The present invention discloses a class of anti-influenza virus compounds, and the use thereof in the preparation of a drug for treating diseases associated with influenza viruses. In particular, the present invention discloses a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 19, 2023
    Publication date: October 26, 2023
    Inventors: Jian XIONG, Chaofeng LONG, Jingjing WANG, Xiaoxin CHEN, KEVIN X. CHEN, Cheng XIE, Peng LI, Xuanjia PENG, Jian Li, Shuhui Chen
  • Anti-influenza virus pyrimidine derivative
    Patent number: 11725009
    Abstract: The present invention discloses a class of anti-influenza virus compounds, and the use thereof in the preparation of a drug for treating diseases associated with influenza viruses. In particular, the present invention discloses a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 24, 2021
    Date of Patent: August 15, 2023
    Assignee: GUANGDONG RAYNOVENT BIOTECH CO., LTD.
    Inventors: Jian Xiong, Chaofeng Long, Jingjing Wang, Xiaoxin Chen, Kevin X Chen, Cheng Xie, Peng Li, Xuanjia Peng, Jian Li, Shuhui Chen
  • Crystal form and salt form of pyridoimidazole compound and preparation method therefor
    Patent number: 11535613
    Abstract: Disclosed are a crystal form and a salt form of a pyrazolopridine compound, and a preparation method therefor. Further included is the use of the crystal form in preparing anti-influenza virus drugs.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: December 27, 2022
    Assignee: GUANGDONG RAYNOVENT BIOTECH CO., LTD.
    Inventors: Jian Xiong, Xiaoxin Chen, Jingjing Wang, Zhuowei Liu, Kevin X Chen, Chengwu Liu, Cheng Xie, Chaofeng Long, Peng Li, Jian Li, Shuhui Chen
  • DOMINANT SALT FORMS OF PYRIMIDINE DERIVATIVES, AND CRYSTAL FORMS THEREOF
    Publication number: 20220380363
    Abstract: Disclosed are sodium salts of pyrimidine derivatives, and a series of crystal forms thereof. The series of crystal forms exhibit a good druggability, such as stability, fluidity, compressibility, etc., and provide a variety of options of APIs for subsequent drug product development.
    Type: Application
    Filed: June 24, 2020
    Publication date: December 1, 2022
    Inventors: Xiaoxin Chen, Chengwu Liu, Zhuowei Liu, Zhenyou Tan, Zhiqiang Liu, Zhiwei Cheng, Chaofeng Long, Jiajun Huang, Guangqiang Zhou
  • Salt form and crystal form of compound as FGFR4 inhibitor and preparation method thereof
    Patent number: 11440903
    Abstract: The present invention provides a salt form, a crystal form, and a preparation method of a compound as an FGFR4 inhibitor and medical uses thereof.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: September 13, 2022
    Assignees: GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD, GUANGDONG XIANQIANG PHARMACEUTICAL CO., LTD
    Inventors: Chaofeng Long, Yang Zhang, Zhengxia Chen, Xiaoxin Chen, Zhuowei Liu, Meibi Dai, Zhiqiang Liu, Shuhui Chen
  • ANTI-INFLUENZA VIRUS PYRIMIDINE DERIVATIVE
    Publication number: 20220135558
    Abstract: The present invention discloses a class of anti-influenza virus compounds, and the use thereof in the preparation of a drug for treating diseases associated with influenza viruses. In particular, the present invention discloses a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 24, 2021
    Publication date: May 5, 2022
    Inventors: Jian Xiong, Chaofeng Long, Jingjing Wang, Xiaoxin Chen, Kevin X Chen, Cheng Xie, Peng Li, Xuanjia Peng, Jian Li, Shuhui Chen
  • Anti-influenza virus pyrimidine derivative
    Patent number: 11136319
    Abstract: The present invention discloses a class of anti-influenza virus compounds, and the use thereof in the preparation of a drug for treating diseases associated with influenza viruses. In particular, the present invention discloses a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: October 5, 2021
    Assignee: Guangdong Raynovent Biotech Co., Ltd.
    Inventors: Jian Xiong, Chaofeng Long, Jingjing Wang, Xiaoxin Chen, Kevin X Chen, Cheng Xie, Peng Li, Xuanjia Peng, Jian Li, Shuhui Chen
  • FGFR4 inhibitor and preparation method and use thereof
    Patent number: 11008292
    Abstract: Provided are a class of compounds as shown in formula (I) as FGFR4 inhibitors, and pharmaceutically acceptable salts thereof, preparation methods therefor and the use thereof in the preparation of drugs for treating FGFR4-related diseases.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: May 18, 2021
    Inventors: Zhengxia Chen, Chaofeng Long, Yang Zhang, Xiaoxin Chen, Yikai Wang, Meibi Dai, Zhuowei Liu, Haixia Zhao, Xing Liu, Guoping Hu, Jian Li, Shuhui Chen
  • SALT FORM AND CRYSTAL FORM OF COMPOUND AS FGFR4 INHIBITOR AND PREPARATION METHOD THEREOF
    Publication number: 20210087181
    Abstract: The present invention provides a salt form, a crystal form, and a preparation method of a compound as an FGFR4 inhibitor and medical uses thereof.
    Type: Application
    Filed: October 30, 2018
    Publication date: March 25, 2021
    Applicants: GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD, GUANGDONG XIANQIANG PHARMACEUTICAL CO., LTD
    Inventors: Chaofeng LONG, Yang ZHANG, Zhengxia CHEN, Xiaoxin CHEN, Zhuowei LIU, Meibi DAI, Zhiqiang LIU, Shuhui CHEN
  • ANTI-INFLUENZA VIRUS PYRIMIDINE DERIVATIVE
    Publication number: 20210032238
    Abstract: The present invention discloses a class of anti-influenza virus compounds, and the use thereof in the preparation of a drug for treating diseases associated with influenza viruses. In particular, the present invention discloses a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 5, 2017
    Publication date: February 4, 2021
    Inventors: Jian Xiong, Chaofeng Long, Jingjing Wang, Xiaoxin Chen, Kevin X Chen, Cheng Xie, Peng Li, Xuanjia Peng, Jian Li, Shuhui Chen
  • CRYSTAL FORM AND SALT FORM OF PYRIDOIMIDAZOLE COMPOUND AND PREPARATION METHOD THEREFOR
    Publication number: 20200407354
    Abstract: Disclosed are a crystal form and a salt form of a pyrazolopridine compound, and a preparation method therefor. Further included is the use of the crystal form in preparing anti-influenza virus drugs.
    Type: Application
    Filed: March 5, 2019
    Publication date: December 31, 2020
    Inventors: Jian Xiong, Xiaoxin Chen, Jingjing Wang, Zhuowei Liu, Kevin X Chen, Chengwu Liu, Cheng Xie, Chaofeng Long, Peng Li, Jian Li, Shuhui Chen
  • Crystal form and salt form of and preparation method for tyrosine kinase inhibitor
    Patent number: 10766862
    Abstract: Disclosed are a crystal form and a salt form of and a preparation method for a tyrosine kinase inhibitor.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: September 8, 2020
    Assignee: Guangdong Raynovent Biotech Co., Ltd.
    Inventors: Chaofeng Long, Zhengxia Chen, Xiaoxin Chen, Yang Zhang, Zhuowei Liu, Shuhui Chen, Jian Li
  • Tyrosine kinase inhibitor and pharmaceutical composition comprising same
    Patent number: 10654808
    Abstract: The present invention relates to a tyrosine kinase inhibitor and a pharmaceutical composition comprising same.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: May 19, 2020
    Assignee: GUANGDONG RAYNOVENT BIOTECH CO., LTD.
    Inventors: Chaofeng Long, Zhengxia Chen, Xiaoxin Chen, Yang Zhang, Zhuowei Liu, Peng Li, Shuhui Chen, Guibai Liang, Cheng Xie, Zhengwei Li, Zhifei Fu, Guoping Hu, Jian Li
  • Hydroxyl purine compounds and use thereof
    Patent number: 10618898
    Abstract: Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNF? inhibitors, in particular, the compounds as shown in formula (I), or tautomers or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: April 14, 2020
    Assignee: GUANGDONG RAYNOVENT BIOTECH CO., LTD.
    Inventors: Linyun Wu, Xiaoxin Chen, Peng Zhang, Xing Liu, Li Zhang, Zhuowei Liu, Shuhui Chen, Chaofeng Long
  • FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF
    Publication number: 20200062716
    Abstract: Provided are a class of compounds as shown in formula (I) as FGFR4 inhibitors, and pharmaceutically acceptable salts thereof, preparation methods therefor and the use thereof in the preparation of drugs for treating FGFR4-related diseases.
    Type: Application
    Filed: November 17, 2017
    Publication date: February 27, 2020
    Applicant: GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD
    Inventors: Zhengxia CHEN, Chaofeng LONG, Yang ZHANG, Xiaoxin CHEN, Yikai WANG, Meibi DAI, Zhuowei LIU, Haixia ZHAO, Xing LIU, Guoping HU, Jian LI, Shuhui CHEN
  • CRYSTAL FORM AND SALT FORM OF AND PREPARATION METHOD FOR TYROSINE KINASE INHIBITOR
    Publication number: 20200024235
    Abstract: Disclosed are a crystal form and a salt form of and a preparation method for a tyrosine kinase inhibitor.
    Type: Application
    Filed: September 29, 2017
    Publication date: January 23, 2020
    Inventors: Chaofeng Long, Zhengxia Chen, Xiaoxin Chen, Yang Zhang, Zhuowei Liu, Shuhui Chen, Jian Li
  • Histone deacetylase inhibitor, and preparation method and use thereof
    Patent number: 10532053
    Abstract: A compound represented by Formula I or pharmaceutically acceptable salt thereof. The present invention relates to a 4-arylamino quinazoline hydroxamic acid compound having a histone deacetylase inhibitory activity, preparation method of the compound, pharmaceutical composition comprising the compound, and use of the compound and the pharmaceutical composition in the preparation of a histone deacetylase inhibitor medicine. The present invention aims at acquiring, via a medicine design and a synthetic technology, a series of selective histone deacetylase inhibitors having good hypotype selectivity and favorable pharmacokinetic characteristics based on optimization of an enzyme surface recognition region and connection region of 4-arylamino quinazoline, thus reducing an effect on normal tissues or cells while improving an antineoplastic activity of the normal tissues or cells. In Formula I, the variables are as described herein.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: January 14, 2020
    Assignee: Guangdong Zhongsheng Pharmaceutical Co., Ltd
    Inventors: Lijuan Chen, Chaofeng Long, Xiaoxin Chen, Zhuowei Liu, Haoyu Ye, Chenshi Xie
  • Pyrrolidine derivatives as PPAR agonists
    Patent number: 10526320
    Abstract: The present invention discloses a class of pyrrolidine derivatives as PPAR agonist, and their use for the treatment of some diseases of PPAR receptor-associated pathways (such as nonalcoholic steatohepatitis and concurrent fibrosis, insulin resistance, primary biliary cholangitis, dyslipidemia, hyperlipidemia, hypercholesterolemia, atherosclerosis, hypertriglyceridemia, cardiovascular disease, obesity or the like). In particular, the present invention discloses a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: January 7, 2020
    Assignee: GUANGDONG RAYNOVENT BIOTECH CO., LTD.
    Inventors: Zhiliang Yuan, Chaofeng Long, Zhigan Jiang, Xiaoxin Chen, Haiying He, Xing Liu, Xiao Zhang, Zhiqiang Liu, Yan Wang, Leilei Gao, Zhen Gong, Jian Li, Shuhui Chen
  • Crystal form A of 7-(cyclopropylmethyl)-1-((()-4-hydroxy-4-methylcyclohexyl)methyl)-3-methyl-1H-purine-2,6-(3H,7H)-dione for treating liver diseases
    Patent number: 10399981
    Abstract: The invention discloses a crystal form A of a compound (I) and a preparation method thereof, and further discloses an application of the crystal form A as a PDE2 or TNF-? inhibitor.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: September 3, 2019
    Assignee: GUANGDONG RAYNOVENT BIOTECH CO., LTD.
    Inventors: Lingyun Wu, Chaofeng Long, Peng Zhang, Xiaoxin Chen, Li Zhang, Zhuowei Liu, Zheng Wang, Shuhui Chen, Lijuan Chen
  • Hydroxyl purine compounds and applications thereof
    Patent number: RE49128
    Abstract: Hydroxyl purine compounds represented by formula (I), tautomers or pharmaceutically acceptable salts thereof, and applications thereof as PDE2 or TNF-? inhibitors.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: July 12, 2022
    Assignee: GUANGDONG RAYNOVENT BIOTECH CO., LTD.
    Inventors: Lingyun Wu, Chaofeng Long, Peng Zhang, Xiaoxin Chen, Li Zhang, Zhuowei Liu, Jian Li, Shuhui Chen